Scarica l'app Stockscreener
3.10
4.03%
0.12
Dopo l'orario di chiusura:
3.12
0.02
+0.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.98
Aprire:
$3.02
Volume 24 ore:
310.04K
Relative Volume:
0.49
Capitalizzazione di mercato:
$112.04M
Reddito:
$106.83M
Utile/perdita netta:
$-39.28M
Rapporto P/E:
-1.4571
EPS:
-2.1275
Flusso di cassa netto:
$-89.31M
1 W Prestazione:
+4.73%
1M Prestazione:
+6.16%
6M Prestazione:
-30.80%
1 anno Prestazione:
+85.07%
Intervallo 1D:
$3.02
$3.18
Intervallo di 1 settimana:
$2.90
$3.5499
Portata 52W:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.10 | 112.04M | 106.83M | -39.28M | -89.31M | -2.1275 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
Volume Summary: Should I invest in Agenus Inc before earningsMarket Performance Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Agenus Q4 2025 earnings preview - MSN
Agenus Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Immuno-oncology initiatives expand to address unmet cancer needs, Agenus asserts - Traders Union
Agenus receives $20M payment from Zydus collaboration By Investing.com - Investing.com Canada
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
Agenus receives $20M payment from Zydus collaboration - Investing.com Nigeria
Agenus (AGEN) Secures $20M Milestone Payment from Zydus Partners - GuruFocus
Agenus Triggers First $20 Million Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - marketscreener.com
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
Agenus warns most metastatic colorectal cancer cases are MSS, calling for innovation to tackle resistance - Traders Union
Benny Johnson is Now The Executive Medical Director at Agenus - Oncodaily
Aug Patterns: Should I invest in Agenus Inc before earningsBuy Signal & Smart Money Movement Tracker - baoquankhu1.vn
How Agenus Inc. stock compares to market leaders2025 Bull vs Bear & Long-Term Safe Return Strategies - Naître et grandir
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - Business Wire
Agenus (AGEN) to Release Earnings on Tuesday - MarketBeat
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
AGEN Technical Analysis & Stock Price Forecast - Intellectia AI
Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC - Finviz
Stock-paid salary boosts Armen’s Agenus (AGEN) share holdings - Stock Titan
How resilient is Agenus Inc. stock in market downturnsJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - mfd.ru
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - BioSpace
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
AGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Agenus Inc. stock could outperform in 2025Weekly Risk Report & Real-Time Volume Trigger Notifications - mfd.ru
Why is Agenus Inc. stock going downJuly 2025 Reactions & Smart Allocation Stock Tips - mfd.ru
Response to the Misleading Open Letter by “Diaspora Leaders”: Statement by Dr. Garo Armen, Founder of the Children of Armenia Fund (COAF) - MassisPost
The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen - Oncodaily
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors - BioSpace
Aug Sentiment: Why is Agenus Inc stock going downQuarterly Trade Summary & Community Supported Trade Ideas - baoquankhu1.vn
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch - MarketBeat
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
Colorectal Cancer is Moving in the Wrong Direction – Agenus - Oncodaily
Agenus Strengthens Medical Affairs Infrastructure to Support Growing Authorized Access to Botensilimab–Balstilimab - Oncodaily
Agenus Lands $141M Zydus Partnership to Power BOT+BAL and U.S. Manufacturing Expansion - Oncodaily
Expansion of Global Medical Affairs to Support BOT+BAL Access – Agenus - Oncodaily
Agenus expands medical affairs to support early access to cancer therapy By Investing.com - Investing.com Nigeria
Looking Into Agenus Inc's Recent Short Interest - Benzinga
Agenus expands medical affairs to support early access to cancer therapy - Investing.com
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program - Intellectia AI
Agenus to Host First 2026 Stakeholder Webcast - The AI Journal
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):